NCT04165122View on ClinicalTrials.gov

Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

August 25, 2021

Study Completion Date

November 1, 2021

Conditions
Herpes Genitalis
Interventions
BIOLOGICAL

HDIT101

i.v. Infusion

DRUG

Valaciclovir

oral application of encapsulated Valaciclovir tablets

BIOLOGICAL

HDIT101 placebo

i.v. Infusion

DRUG

Valaciclovir placebo

oral application of encapsulated Valaciclovir placebo tablets

Trial Locations (8)

10629

emovis GmbH, Berlin

10777

Praxis Jessen2+Kollegen, Berlin

20146

ICH Grindel, Hamburg

44787

"WIR Walk In Ruhr im St. Elisabeth Hospital", Bochum

50674

Dr. Scholten und Schneeweiß GbR, Cologne

60596

Infektio Research GmbH & Co. KG, Frankfurt

79106

Universitätsklinikum Freiburg, Medizin II, Infektiologie, Freiburg im Breisgau

80336

Prinzmed, München

Sponsors
All Listed Sponsors
lead

Heidelberg ImmunoTherapeutics GmbH

INDUSTRY